NCAM1 and COVID-19: However, the percentage of CD16+CD56+ natural killer cells (Figure 2B, p<0.001) was found to be significantly higher in the peripheral blood of COVID-19 patients, compared to both the HS and VS (Figure 2B, p<0.001).